Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines

• DOI: 10.3389/fimmu.2022.1032356
• Publication Date: 2022-11-28T05:15:31Z
• Authors: Nouf Alluqmani; Anna Jirovec; Zaid Taha; Oliver Varette; Andrew Chen; Daniel Serrano; Glib Maznyi; Sarwat Khan; Nicole E. Forbes; Rozanne Arulanandam; Rebecca C. Auer; Jean-Simon Diallo
• Keywords: Cancer Immunotherapy

Oncolytic viruses (OVs) are promising anticancer treatments that specifically replicate in and kill cancer cells have profound immunostimulatory effects. We previously reported the potential of vanadium-based compounds such as vanadyl sulfate (VS) enhancers OV immunotherapy. These compounds, conjunction with RNA-based OVs oncolytic vesicular stomatitis virus (VSVΔ51), improve viral spread oncolysis, leading to long-term antitumor immunity prolonged survival resistant tumor models. This effect is associated a virus-induced antiviral type I IFN response shifting towards II presence vanadium. Here, we investigated systemic impact VS+VSVΔ51 combination therapy understand immunological mechanism action improved responses. significantly increased levels IFN-γ IL-6, antigen-specific T-cell Supported by profiling proof concept for design more effective therapeutic regimens, found local delivery IL-12 using VSVΔ51 VS further outcomes syngeneic CT26WT colon model.